Ketamine - more mechanisms of action than just NMDA blockade

Trends in Anaesthesia and Critical Care

Volumn 4, Issue 2-3, 2014, Pages 76-81

  Sleigh, Jamie ^a   Harvey, Martyn ^a   Voss, Logan ^a   Denny, Bill ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anaesthesia; Analgesia; Ketamine; Mechanisms of action

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANESTHETIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DIZOCILPINE; G PROTEIN COUPLED RECEPTOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN C FOS; PROTEIN C JUN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RGS4 PROTEIN; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND;

ANALGESIA; ANESTHESIA; APOPTOSIS; BEHAVIOR CHANGE; BRAIN STEM; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DEPRESSION; CEREBELLUM; CHRONIC PAIN; DIENCEPHALON; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; EXCITOTOXICITY; HUMAN; HYPNOSIS; IMMEDIATE EARLY GENE; LIMBIC SYSTEM; NERVE CELL; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL CORD; SYMPATHETIC TONE; THALAMUS; UNCONSCIOUSNESS; ANESTHESIA INDUCTION; ANESTHESIA MECHANISM; ANTIDEPRESSANT ACTIVITY; DISEASE CONTROL; DRUG EFFECT; DRUG POTENCY; PAIN ASSESSMENT; PROTEIN FUNCTION;

EID: 84901491757     PISSN: 22108440     EISSN: 22108467     Source Type: Journal    
DOI: 10.1016/j.tacc.2014.03.002     Document Type: Review

References (61)

1. Domino E.F., Chodoff P., Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965, 6:279-291. Epub 1965/05/01.
2. MacDonald J.F., Miljkovic Z., Pennefather P. Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. JNeurophysiol 1987, 58(2):251-266. Epub 1987/08/01.
3. Hirota K. Special cases: ketamine, nitrous oxide and xenon. Best Pract Res Clin Anaesthesiol 2006, 20(1):69-79. Epub 2006/04/26.
4. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62(1):35-41. Epub 2011/09/13.
5. Dorandeu F. Happy 50th anniversary ketamine. CNS Neurosci Ther 2013, 19(6):369.
6. Cai Y.C., Ma L., Fan G.H., Zhao J., Jiang L.Z., Pei G. Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors. Mol Pharmacol 1997, 51(4):583-587. Epub 1997/04/01.
7. Lydic R., Baghdoyan H.A. Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep. Sleep 2002, 25(6):617-622. Epub 2002/09/13.
8. Yamakura T., Chavez-Noriega L.E., Harris R.A. Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 2000, 92(4):1144-1153. Epub 2001/02/07.
9. Kubota T., Anzawa N., Hirota K., Yoshida H., Kushikata T., Matsuki A. Effects of ketamine and pentobarbital on noradrenaline release from the medial prefrontal cortex in rats. Can J Anaesth 1999, 46(4):388-392. Epub 1999/05/08.
10. Kamiyama H., Matsumoto M., Otani S., Kimura S.I., Shimamura K.I., Ishikawa S., et al. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience 2011, 177:159-169. Epub 2010/12/18.
11. Wang M., Wong A.H., Liu F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res 2012, 1476:154-163. Epub 2012/04/05.
12. Kussius C.L., Kaur N., Popescu G.K. Pregnanolone sulfate promotes desensitization of activated NMDA receptors. JNeurosci 2009, 29(21):6819-6827. Epub 2009/05/29.
13. Yamakage M., Hirshman C.A., Croxton T.L. Inhibitory effects of thiopental, ketamine, and propofol on voltage-dependent Ca2+ channels in porcine tracheal smooth muscle cells. Anesthesiology 1995, 83(6):1274-1282. Epub 1995/12/01.
14. Xue J.G., Masuoka T., Gong X.D., Chen K.S., Yanagawa Y., Law S.K., et al. NMDA receptor activation enhances inhibitory GABAergic transmission onto hippocampal pyramidal neurons via presynaptic and postsynaptic mechanisms. JNeurophysiol 2011, 105(6):2897-2906. Epub 2011/04/08.
15. Ogden K.K., Traynelis S.F. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 2011, 32(12):726-733. Epub 2011/10/15.
16. Vance K.M., Simorowski N., Traynelis S.F., Furukawa H. Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat Commun 2011, 2:294. Epub 2011/04/28.
17. Weigt H.U., Adolph O., Georgieff M., Georgieff E.M., Fohr K.J. Evidence that Xenon does not produce open channel blockade of the NMDA receptor. JNeurophysiol 2008, 99(4):1983-1987. Epub 2008/02/01.
18. Bolshakov K.V., Gmiro V.E., Tikhonov D.B., Magazanik L.G. Determinants of trapping block of N-methyl-d-aspartate receptor channels. JNeurochem 2003, 87(1):56-65. Epub 2003/09/13.
19. Lanthorn T.H., Mealing G.A., Morley P. Differences in degree of trapping between AR-R15896 and other uncompetitive NMDA receptor antagonists. Amino Acids 2000, 19(1):173-175. Epub 2000/10/12.
20. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007, 8(5):621-632. Epub 2007/05/17.
21. Belluardo N., Mudo G., Dell'Albani P., Jiang X.H., Condorelli D.F. NMDA receptor-dependent and -independent immediate early gene expression induced by focal mechanical brain injury. Neurochem Int 1995, 26(5):443-453. Epub 1995/05/01.
22. Mei X.P., Wang W., Wang W., Zhu C., Chen L., Zhang T., et al. Combining ketamine with astrocytic inhibitor as a potential analgesic strategy for neuropathic pain ketamine, astrocytic inhibitor and pain. Mol Pain 2010, 6:50.
23. Ohnesorge H., Feng Z., Zitta K., Steinfath M., Albrecht M., Bein B. Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice. PLoS One 2013, 8(11):e79567. Epub 2013/11/14.
24. Hayashi Y., Kawaji K., Sun L., Zhang X., Koyano K., Yokoyama T., et al. Microglial Ca(2+)-activated K(+) channels are possible molecular targets for the analgesic effects of S-ketamine on neuropathic pain. JNeurosci 2011, 31(48):17370-17382.
25. Mei X., Wang W., Wang W., Li Y., Zhang H., Wu S., et al. Inhibiting astrocytic activation: a novel analgesic mechanism of ketamine at the spinal level?. JNeurochem 2009, 109(6):1691-1700.
26. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Barbosa L.M., Andreazza A.C., et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(1):140-144.
27. Yang C., Hu Y.M., Zhou Z.Q., Zhang G.F., Yang J.J. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci 2013, 118(1):3-8.
28. Sorce S., Schiavone S., Tucci P., Colaianna M., Jaquet V., Cuomo V., et al. The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses. JNeurosci 2010, 30(34):11317-11325. Epub 2010/08/27.
29. Stratinaki M., Varidaki A., Mitsi V., Ghose S., Magida J., Dias C., et al. Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci U S A 2013, 110(20):8254-8259. Epub 2013/05/01.
30. Clements J.A., Nimmo W.S., Grant I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. JPharm Sci 1982, 71(5):539-542. Epub 1982/05/01.
31. Mion G., Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 2013, 19(6):370-380.
32. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. JNeurosci 2007, 27(43):11496-11500. Epub 2007/10/26.
33. Kelland M.D., Soltis R.P., Boldry R.C., Walters J.R. Behavioral and electrophysiological comparison of ketamine with dizocilpine in the rat. Physiol Behav 1993, 54(3):547-554. Epub 1993/09/01.
34. Petrenko A.B., Yamakura T., Fujiwara N., Askalany A.R., Baba H., Sakimura K. Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit. Anesth Analg 2004, 99(4):1136-1140. Tableof contents. Epub 2004/09/24.
35. Petrenko A.B., Yamakura T., Kohno T., Sakimura K., Baba H. Increased brain monoaminergic tone after the NMDA receptor GluN2A subunit gene knockout is responsible for resistance to the hypnotic effect of nitrous oxide. Eur J Pharmacol 2013, 698(1-3):200-205. Epub 2012/11/06.
36. Chen X., Shu S., Bayliss D.A. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. JNeurosci 2009, 29(3):600-609. Epub 2009/01/23.
37. Zhou C., Douglas J.E., Kumar N.N., Shu S., Bayliss D.A., Chen X. Forebrain HCN1 channels contribute to hypnotic actions of ketamine. Anesthesiology 2013, 118(4):785-795. Epub 2013/02/05.
38. Lu J., Nelson L.E., Franks N., Maze M., Chamberlin N.L., Saper C.B. Role of endogenous sleep-wake and analgesic systems in anesthesia. JComp Neurol 2008, 508(4):648-662. Epub 2008/04/03.
39. Nelson C.L., Burk J.A., Bruno J.P., Sarter M. Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacol (Berl) 2002, 161(2):168-179. Epub 2002/05/01.
40. Dahan A., Olofsen E., Sigtermans M., Noppers I., Niesters M., Aarts L., et al. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011, 15(3):258-267. Epub 2010/07/20.
41. Niesters M., Martini C., Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 2014, 77(2):357-367.
42. Rabben T., Oye I. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. Eur J Pain 2001, 5(3):233-240. Epub 2001/09/18.
43. Olofsen E., Noppers I., Niesters M., Kharasch E., Aarts L., Sarton E., et al. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 2012, 117(2):353-364. Epub 2012/06/14.
44. Niesters M., Dahan A., Swartjes M., Noppers I., Fillingim R.B., Aarts L., et al. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain 2011, 152(3):656-663. Epub 2011/01/18.
45. Noppers I., Niesters M., Aarts L., Smith T., Sarton E., Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010, 11(14):2417-2429. Epub 2010/09/11.
46. Rabben T., Skjelbred P., Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. JPharmacol Exp Ther 1999, 289(2):1060-1066. Epub 1999/04/24.
47. Petrenko A.B., Yamakura T., Baba H., Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003, 97(4):1108-1116. Epub 2003/09/23.
48. Sarton E., Teppema L.J., Olievier C., Nieuwenhuijs D., Matthes H.W., Kieffer B.L., et al. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001, 93(6):1495-1500. Tableof contents. Epub 2001/12/01.
49. Shikanai H., Hiraide S., Kamiyama H., Kiya T., Oda K., Goto Y., et al. Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats. JAnesth 2013, Epub 2013/10/12.
50. Blednov Y.A., Stoffel M., Alva H., Harris R.A. Apervasive mechanism for analgesia: activation of GIRK2 channels. Proc Natl Acad Sci U S A 2003, 100(1):277-282. Epub 2002/12/21.
51. Gupta A., Devi L.A., Gomes I. Potentiation of mu-opioid receptor-mediated signaling by ketamine. JNeurochem 2011, 119(2):294-302. Epub 2011/06/23.
52. Koizuka S., Obata H., Sasaki M., Saito S., Goto F. Systemic ketamine inhibits hypersensitivity after surgery via descending inhibitory pathways in rats. Can J Anaesth 2005, 52(5):498-505.
53. Gordh T., Karlsten R., Kristensen J. Intervention with spinal NMDA, adenosine, and NO systems for pain modulation. Ann Med 1995, 27(2):229-234.
54. Backonja M., Arndt G., Gombar K.A., Check B., Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994, 56:51-57.
55. Warncke T., Stubhaug A., Jorum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain 1997, 72(1-2):99-106. Epub 1997/08/01.
56. Remerand F., Le Tendre C., Baud A., Couvret C., Pourrat X., Favard L., et al. The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study. Anesth Analg 2009, 109(6):1963-1971. Epub 2009/11/20.
57. Romero-Sandoval E.A. Depression and pain: does ketamine improve the quality of life of patients in chronic pain by targeting their mood?. Anesthesiology 2011, 115(4):687-688. Epub 2011/08/16.
58. Wang J., Goffer Y., Xu D., Tukey D.S., Shamir D.B., Eberle S.E., et al. Asingle subanesthetic dose of ketamine relieves depression-like behaviors induced byneuropathic pain in rats. Anesthesiology 2011, 115(4):812-821. Epub 2011/09/22.
59. Geisser M.E., Roth R.S., Theisen M.E., Robinson M.E., Riley J.L. Negative affect, self-report of depressive symptoms, and clinical depression: relation to the experience of chronic pain. Clin J Pain 2000, 16(2):110-120. Epub 2000/06/28.
60. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001, 429(1-3):23-37.
61. Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Metallele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012, 71(11):996-1005. Epub 2011/11/01.